Last updated on June 2005

Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease


Brief description of study

OBJECTIVES: I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease.

Detailed Study Description

PROTOCOL OUTLINE: Patients are treated with intravenous glucocerebrosidase every 2 weeks. The dose is based on clinical severity of disease and response to therapy.

Clinical Study Identifier: NCT00004293

Find a site near you

Start Over

University of Pittsburgh

Pittsburgh, PA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.